Early Access — free while we kick the tires
EdgarHawk

ANDO GORAN

Director

Director
1 filing analyzed · 1 company · Latest 2024-08-21

Companies

Company Buys Sells Direction
EyePoint Pharmaceuticals, Inc. EYPT 1 0 Net buying

Activity

August 2024
Buy
5,000 shares
$39,750
Significance 6/10

Director Ando Goran buys 5,000 shares of EYPT at $7.95; 3 other insiders also bought within 14 days.

Ando Goran purchased 5,000 shares at $7.95 on 2024-08-21, expanding his holdings from 8,150 to 13,150 shares (+61.3%). This buy-side activity occurs in a cluster context: 3 other insiders also purchased shares within the past 14 days. The company is unprofitable (net income $-30.8M over the latest full fiscal year), though it posted quarterly revenue of $9.5M and annual revenue growth of +11.1%. The stock currently trades at $9.05, down 69.5% from its 52-week high of $29.71 and modestly positive on a 30-day basis (+1.3%). The convergence of multiple insider buys at depressed valuations alongside operational losses and recent momentum erosion warrants investor scrutiny of management's confidence thesis versus the underlying business fundamentals.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access